Gyre Therapeutics (GYRE) Operating Expenses (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Operating Expenses data on file, last reported at $31.9 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $31.9 million, up 61.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $119.7 million (up 31.18% YoY), and the FY2025 annual result was $105.1 million, up 17.31% from the prior year.
• Operating Expenses declined to $31.9 million in Q1 2026 per GYRE's latest filing, from $40.8 million in the prior quarter.
• Over five years, Operating Expenses peaked at $124.0 million in Q4 2022 and troughed at -$51.5 million in Q2 2022.
• A 5-year average of $29.5 million and a median of $21.3 million in 2024 frame the typical range for Operating Expenses.
• On a YoY basis, Operating Expenses climbed as much as 444.79% in 2022 and fell as far as 344.84% in 2022.
• A 5-year view of Operating Expenses shows it stood at $124.0 million in 2022, then decreased by 4.18% to $118.8 million in 2023, then sank by 74.82% to $29.9 million in 2024, then jumped by 36.22% to $40.8 million in 2025, then slipped by 21.78% to $31.9 million in 2026.
• Business Quant data shows GYRE's Operating Expenses at $31.9 million in Q1 2026, $40.8 million in Q4 2025, and $23.6 million in Q3 2025.